Table 2.
Intracellular cancer hallmarks and p73 functions in specific cancers
| Cancer | Apoptosis, cell cycle | Replicative Immortality | Genomic instability, DSB response | Altered metabolism | Role of p73 isoforms in cancer | TP73 in tumor compared to normal tissue |
|---|---|---|---|---|---|---|
| Non-small cell lung carcinoma (NSCLC) | [24–29] | [30, 31] | [32, 33] | [34–36] | ||
| Lung adenocarcinomas | [27] | [20] | [37, 38] | 2.95 | ||
| Hepatocellular carcinoma (HCC) | [39] | |||||
| Cervix carcinoma | [40–42] | [41] | [22, 43, 44] | 15.2 | ||
| Melanoma | [45] | [46] | ||||
| Osteosarcoma | [47–51] | [52, 53] | [54, 55] | 5.4 | ||
| Glioblastoma | [56, 57] | [58, 59] | 5.2 | |||
| Medulloblastoma | [60, 61] | [62] | – | |||
| B-cell lymphoma | [63] | [64] | [65] | [66] | 33.6 | |
| T-cell lymphoma | [67, 68] | |||||
| Acute myeloid leukemia | [69–72] | |||||
| Chronic myelogenous leukemia (CML) | [73–75] | [73] | ||||
| Breast cancer | [76–79] | [80] | [81] | [82] | 1.2 | |
| Colorectal cancer | [25, 78, 83, 84] | [85–87] | [88] | [84, 89] | 9.6 | |
| Esophageal adenocarcinoma | [90] | [91–93] | [94] | 1.1 | ||
| Thyroid cancer | [95] | |||||
| Ovarian cancer | [96, 97] | [98] | 4.1 | |||
| Pancreatic cancer | [99, 100] | 3.15 | ||||
| Neuroblastoma | [26, 101–103] | [104] | ||||
| Squamous carcinoma | [105, 106] | [107, 108] | 1.26 |
The rightmost column represents the Tp73 expression in tumor tissue (Tp73Tum) in comparison to normal tissue (Tp73Norm) as a ration log2(Tp73Tum + 1)/log2(Tp73Norm + 1) [23]